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Background: New drugs are constantly sought after to improve the survival of patients with malignant gliomas.
The ideal substance would selectively target tumor cells without eliciting toxic side effects. Here, we report on the
anti-proliferative, anti-migratory, and anti-invasive properties of the natural, nontoxic compound Curcumin
observed in five human glioblastoma (GBM) cell lines in vitro.
Methods: We used monolayer wound healing assays, modified Boyden chamber trans-well assays, and cell growth
assays to quantify cell migration, invasion, and proliferation in the absence or presence of Curcumin at various
concentrations. Levels of the transcription factor phospho-STAT3, a potential target of Curcumin, were determined
by sandwich-ELISA. Subsequent effects on transcription of genes regulating the cell cycle were analyzed by
quantitative real-time PCR. Effects on apoptosis were determined by caspase assays.
Results: Curcumin potently inhibited GBM cell proliferation as well as migration and invasion in all cell lines
contingent on dose. Simultaneously, levels of the biologically active phospho-STAT3 were decreased and correlated
with reduced transcription of the cell cycle regulating gene c-Myc and proliferation marking Ki-67, pointing to a
potential mechanism by which Curcumin slows tumor growth.
Conclusions: Curcumin is part of the diet of millions of people every day and is without known toxic side effects.
Our data show that Curcumin bears anti-proliferative, anti-migratory, and anti-invasive properties against GBM cells
in vitro. These results warrant further in vivo analyses and indicate a potential role of Curcumin in the treatment of
malignant gliomas.
Background
Although the introduction of temozolomide treatment in
addition to radiotherapy after surgical resection has
improved survival in patients with glioblastoma (GBM),
tumor recurrence is inevitable [1,2]. After tumor recur-
rence, current as well as novel chemotherapeutic regimens
are of modest benefit, and overall survival rates remain
poor [3]. Only a subpopulation of patients (with a methy-
lated O(6)-methylguanine-DNA methyltransferase
(MGMT) gene promoter) may benefit from dose-intensi-
fied temozolomide treatment with added lomustine in
terms of overall survival, at the cost of increased toxicity
[4]. Therefore, new drugs that are effective in a wider
range of GBM patients, most preferably without inducing
additional toxicity, continue to be sought.
Curcumin, derived from the rhizome of the plant
Curcuma longa, is the major pharmacologically active
component of the spice turmeric and potentially repre-
sents one of those drugs [5]. Being the main ingredient
of curries and thus part of the everyday diet of millions
of people, Curcumin is considered a safe agent in
humans [5,6]. Recent preclinical as well as first clinical
reports have indicated that Curcumin may be effective
in the treatment of various cancers [7-10]. The underly-
ing mechanisms of this efficacy are still under investiga-
tion, but recently an association with the JAK/STAT3
pathway has been proposed [11].
With this study, we aimed to assess the potential
effects of treatment with Curcumin on the hallmarks of
GBM, i.e. tumor cell proliferation, migration, and
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Cell lines studied were derived from human primary
(A-172, MZ-18) or recurrent GBM (MZ-54, MZ-256,
MZ-304) and grown in high glucose (4.5 g/l) DMEM
with 10% heat inactivated fetal calf serum (FCS),
100 U/ml penicillin, and 100 mg/ml streptomycin.
Cells were cultured at 37°C in a humidified atmo-
sphere composed of 5% CO2 and 95% air.
Chemical reagents
Curcumin (94% pure) and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) were pur-
chased from LKT (LKT laboratories, St. Paul, MN,
USA) and Sigma-Aldrich (Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany), respectively. For stock solutions,
Curcumin was dissolved in DMSO at 10 mg/mL and
stored at -20°C; MTT was dissolved in PBS at 5 mg/mL
and stored at 4°C.
Cell growth and proliferation assay
Cell viability was determined using the methyl-thiazolyl
tetrazolium bromide (MTT) quantitative colorimetric
assay. The viable cell number is directly proportional to
the production of insoluble purple formazan through
cleavage of the tetrazolium ring by mitochondrial
enzymes. The coversion can be measured spectrophoto-
metrically (l = 560 nm) upon solubilization with 1/24 1
M HCl/95% EtOH.
Cells were seeded at a density of 5,000 cells/well in a 96-
well-plate (Greiner Bio-One, Frickenhausen, Germany)
and were allowed to grow in medium containing 10% FCS
for 24 hours. Thereafter, cells were incubated with Curcu-
min at concentrations of 0, 10, 20, and 50 μM. Cells were
allowed to grow for various periods of time (6, 12, 24, 48,
and 72 hours). Thereafter, cells were incubated with MTT
(0.5 mg/ml) for 3 hours. Cell growth was determined by
measuring absorption at indicated periods of time using a
multi-well scanning reader (Tecan GmbH, Crailsheim,
Germany). For each experiment, 18 wells were allocated to
one treatment or control group.
Wound healing assay
Monolayer wound healing assays, a.k.a. scratch assays,
were performed by plating cells in 6-well culture dishes
(Greiner Bio-One, Frickenhausen, Germany) as
described previously [12].
Briefly, 15 - 20 × 10
5 cells were seeded per well. After
the cells were allowed to attach and reach 80% subcon-
fluency, they were incubated with starvation medium
containing 2% FCS for 24 hours prior to further incuba-
t i o nf o r2h o u r si ns t a r v a t i o nm e d i u mi nt h ea b s e n c e
(control) or presence of Curcumin at concentrations of
10, 20, and 50 μM, before a scratch was performed
through the cell monolayer using a yellow pipet tip.
Cells were washed with PBS before photographs of the
scratch area were taken in treated and untreated cells
using a Nikon Eclipse TE2000-S microscope (Nikon
GmbH, Düsseldorf, Germany). For each well, two differ-
ent areas of the scratch were photographed and their
location on the dish was noted. Cells were further incu-
bated for 12 hours in starvation medium before the
exact same areas were re-photographed and cells enter-
ing the denuded area were counted.
Invasion assay
Invasion of tumor cells was evaluated using a Matrigel-
coated modified Boyden chamber (Biocoat™ Matrigel™
Invasion Chamber; Becton Dickinson GmbH, Heidel-
berg, Germany) according to the manufacturer’s advice.
Briefly, 25,000 cells untreated or treated with Curcu-
min at concentrations of 10 and 20 μM were seeded
into the upper well of the chamber containing serum-
free culture medium. The lower well was filled with
culture medium containing 10% FCS. After 24 hours
cells on the upper surface of the well were removed and
cells on the lower surface were fixed in 95% ethanol and
stained with 0.1% crystal violet. Then, the transmigrated
cells were counted using a Nikon Eclipse TE2000-S
microscope (Nikon GmbH, Düsseldorf, Germany). For
each experiment, 10 random high power fields were
counted.
Sandwich ELISA
To elucidate the potential mechanism of action, we
examined the effect of Curcumin treatment on the
phosphorylation status of the transcription factor
STAT3 employing a sandwich-ELISA kit (PathScan®
Phospho-Stat3 (Tyr705) Sandwich ELISA Antibody Pair
#7146; Cell Signaling Technology Inc., Danvers, MA)
according to the manufacturer’s advice.
Briefly, after coating the microplate wells, cells were
seeded on 10 cm Ø culture dishes and were incubated
for 2 h with Curcumin at 0, 10, 20, or 50 μM, respec-
tively. Cells were then lysed using ice-cold lysis buffer;
the lysates were further sonicated on ice. Then, 100 μl
of the respective lysates were added to a microplate well
and incubated at 37°C for 2 h before the well was
washed, and first a detection antibody (incubation: 1 h)
and then a secondary antibody (incubation: 30 min) was
added to each well. After finally adding TMB substrate
and STOP solution, absorbance of each well was mea-
sured at l = 450 nm.
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The quantification of mRNA levels was carried out using
a real-time fluorescence detection method (TaqMan®) as
described previously [13]. Quantitative real-time PCR
plots the PCR product on a curve as it accumulates at
each cycle of the reaction, in contrast to conventional
PCR, which only displays PCR product at the final cycle.
Total RNA was reversely transcribed using SuperScript™
III reverse transcriptase (Invitrogen GmbH, Karlsruhe,
Germany). Subsequently, approximately 30 ng of cDNA
were subjected to amplification using an ABI Prism 7500
sequence detection system with TaqMan® assays (Applied
Biosystems Inc, Foster City, CA) according to the manu-
facturer’s advice. Primers and probes were designed to
specifically amplify mRNA of c-Myc (Hs01032443_m1
and Hs00905030_m1), Ki-67 (Hs00153408_m1 and
Hs01032435_g1) as well as mRNA of a reference gene,
HPRT-1 (Hs99999909_m1). The ratios of c-Myc or Ki-67
RNA to the reference HPRT-1 represent their relative




Effector caspase activity of treated and untreated cells
was determined as described previously [15]. Briefly, buf-
fer containing DEVD-7-amino-4-methylcoumarin (AMC)
was added to the lysates of treated (24 h) and untreated
cells at a final concentration of 10 μmol/L. Cells treated
with staurosporine (STS) at 3 μM for 16 h served as con-
trol. Cells were incubated for 2 h at 37°C in the dark and
the generation of the fluorescent AMC cleavage product
was measured at 380 nm excitation and 465 nm emis-
sion, using a fluorescence plate reader. Fluorescence of
blanks containing no cell lysate was subtracted from the
values. Protein content was determined using the Pierce
Coomassie Plus Protein Assay reagent (KMF, Cologne,
Germany). Caspase activity is expressed as change in
fluorescence units per microgram protein per hour.
Statistical analysis
All data are expressed as means ± standard error of the
mean (SEM) of at least 3 independent experiments. Sta-
tistical differences were evaluated by 1-way ANOVA fol-
lowed by Tukey’s test using commercially available
software (SPSS 17.0; SPSS Inc., Chicago, Ill.). P values <
0.05 were considered statistically significant.
Results
Curcumin is a potent inhibitor of GBM proliferation
To examine whether treatment with Curcumin influ-
ences tumor cell proliferation, we employed MTT
assays. In a dose-dependent fashion, cell growth was
reduced in all cell lines as shown by cell proliferation
graphs depicted in Figure 1A. Already, low dose
(10 μM) treatment with Curcumin significantly reduced
cell growth after 72 h by 21% - 36% (MZ-18 and A-172,
respectively). An even stronger effect was observed after
incubation with 20 or 50 μM Curcumin, reducing cell
growth by at least 32% (20 μM, MZ-304) to 81%
(50 μM, A-172). Details are provided in Figure 1B.
Curcumin reduces intracellular levels of the transcription
factor STAT3, resulting in reduced transcription of cell
cycle regulating genes
We hypothesized that the effects on cell proliferation
induced by Curcumin may be explained by its interfer-
ence with the JAK/STAT3-pathway, as Curcumin was
shown to activate the tyrosine phosphatase SHP-2, a
negative regulator of JAK activity [16]. STAT3, activated
by JAKs, is a nuclear transcription factor, known to reg-
ulate genes involved in cell cycle progression [17]. We
previously reported that STAT3 is constitutively acti-
vated in the cell lines used [18]. In parallel to our obser-
vation of reduced cell proliferation, we found reduced
transcription of cell cycle regulating c-Myc already after
2 h of Curcumin treatment (Figure 1C). Correspond-
ingly, quantitative real-time PCR also revealed a
decrease of Ki-67 mRNA synthesis after 24 h incubation
with Curcumin (Figure 1D). In concordance with the
reduced transcription of cell cycle regulating genes, we
observed a dose-dependent reduction of phosphorylated
(active) STAT3 levels after 2 h treatment with Curcu-
min in all cell lines investigated as determined by
ELISA. When normalized to untreated controls, phos-
pho-STAT3 levels declined to 41-83% after treatment
with 10 μM Curcumin and to 18-35% after treatment
with 20 μM Curcumin. Phospho-STAT3 levels even-
tually diminished to 0-16% after treatment with 50 μM
Curcumin (Figure 2A).
To examine whether STAT3 inhibition by Curcumin
is short-lived or long-lasting, we additionally performed
wash out experiments with MZ-256 GBM cells. As indi-
cated in Figure 2B, the continuous presence of 50 μM
Curcumin decreased STAT3 tyrosine-705 phosphoryla-
tion completely for over 24 h, while after withdrawal of
the inhibitor the active form of the transcription factor
STAT3 began to resurface at 12 h after the wash out to
reach 60% of its control level after 24 h. This experi-
ment revealed that the estimated half-life of Curcumin
in cultured GBM cells is about 24 h. It can therefore be
concluded that STAT3 inhibition by Curcumin is transi-
ent, and Curcumin has to be sustained continuously for
effective treatment.
Curcumin inhibits GBM migration and invasion
Having established a link between Curcumin and phos-
pho-STAT3, we further investigated the effect of Cur-
cumin on the migratory behavior of GBM cells by
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Page 3 of 8Figure 1 Cell proliferation. A. Line graphs showing representative growth curves of human GBM cells when treated with or without Curcumin
at various concentrations (10 μM, 20 μM, or 50 μM, respectively). B. Bar graphs showing dose-dependency of cell viability when treated with
Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) after 72 h. Data are from three independent experiments. Controls are set at 100%.
Statistically significant differences compared to controls are marked by asterisks (* P < 0.05, ** P < 0.01, *** P < 0.001). Unless indicated by n.s.,
differences between groups are statistically significant (P < 0.05 or less). C. Bar graphs showing decrease in genomic transcription of c-Myc after
treatment with Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) for 2 h. Data are from three independent experiments. Controls are set at
100%. An asterisk indicates differences that are statistically significant compared to controls. D. Bar graphs showing decrease in genomic
transcription of Ki-67 after treatment with Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) for 24 h. Data are from three independent
experiments. Controls are set at 100%. An asterisk indicates differences that are statistically significant compared to controls. E. Bar graphs
showing effect of treatment with Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) for 24 h on caspase 3-like activity. Data are from three
independent experiments. Staurosporine (STS) treated cells served as a positive control for induction of apoptosis. An asterisk indicates
differences that are statistically significant compared to untreated cells.
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Page 4 of 8performing wound healing assays. Here, we found that
Curcumin treatment significantly inhibited cell migra-
tion in all cell lines in a dose-dependent fashion
(Figure 2B). In addition, we performed trans-well
assays using modified Boyden chambers to investigate
the effects of Curcumin on the invasive properties of
GBM cells. Our findings here were comparable to the
wound healing assays with a dramatically reduced
invasiveness of cells after treatment with Curcumin. At
a concentration of 50 μM Curcumin, only in the
MZ-304 cell line there were a few cells invading
trough the matrigel membrane; in all other cell lines,
the capability to invade the membrane was completely
abolished (Figure 2C).
Effect of Curcumin on apoptosis in GBM cells
To investigate whether curcumin may not only inhibit
cell proliferation, but also induce apoptosis in GBM
cells, a caspase 3-like DEVD cleavage assay was
employed with staurosporine (STS) serving as a positive
control for induction of apoptosis. After treatment with
Curcumin, we observed neglibigle induction of effector
caspases, whereas STS induced significant DEVD clea-
vage activity (Figure 1E).
Figure 2 Cell migration/invasion and STAT3 levels. A. Bar graphs showing a dose-dependent reduction of intracellular levels of
phosphorylated STAT3 by Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) determined by ELISA. Data are from four independent
experiments. An asterisk indicates differences that are statistically significant compared to controls. B. Bar graphs showing restoration of
phosphorylated STAT3 levels in MZ-256 cells following treatment with Curcumin (0, 10, 20, 50 μM) for 2 h as determined by sandwich ELISA. In
cells treated with 10 or 20 μM, normal levels are restored after 12 h, and they further increase after 24 h. Phosphorylated STAT3 levels remain
low for up to 24 h in cells treated with 50 μM Curcumin. When in contrast cells are treated with Curcumin continuously for 24 h,
phosphorylated STAT3 levels remain low. Data are from three independent experiments. An asterisk indicates differences that are statistically
significant compared to controls. C. Bar graphs showing a dose-dependent reduction of GBM cell motility by Curcumin (0, 10 μM, or 20 μM,
respectively) determined by wound healing assays. Data are from three independent experiments. An asterisk indicates differences that are
statistically significant compared to controls. D. Bar graphs showing a dose-dependent reduction of the invasive capability of GBM cells by
Curcumin (0, 10 μM, 20 μM, or 50 μM, respectively) determined by modified Boyden chamber assays. Data are from three independent
experiments. An asterisk indicates differences that are statistically significant compared to controls.
Senft et al. BMC Cancer 2010, 10:491
http://www.biomedcentral.com/1471-2407/10/491
Page 5 of 8Discussion
Until today, glioblastomas are incurable malignant
tumors. Neither the implementation of multimodal
therapies nor advances in surgical techniques have
helped to push median survival of affected patients
above the 2-year boundary [1,19,20]. Therefore, new
therapeutic strategies are constantly under investigation.
Ideally, a chemotherapeutic drug would prove effica-
cious selectively against tumor cells without inducing
unwanted side effects.
Although long-term studies in both animals and
humans are lacking, Curcumin, being a natural com-
pound and the main ingredient of turmeric, commonly
known as “curry”, is generally regarded as a safe agent
[21]. Therapeutic effects on various cancers have been
reported [7,22]. Besides showing an inherent cytotoxi-
city against malignant cells, Curcumin has additionally
been shown to modulate radio- and chemosensitivity of
cancer cells [10,23-25]. With regards to its potential
anti-cancer properties, epidemiological data show a gen-
erally low incidence in several types of cancer in popu-
lations consuming around 100-200 mg/day [26].
A recent phase I clinical trial in breast cancer demon-
strated safety of a daily intake of 6-8 g Curcumin [27].
Several molecular targets of Curcumin have been impli-
cated in the anticancer effects of Curcumin, and Curcu-
min was suggested to affect a number of molecular
signaling cascades [21,28,29].
In this study, we could show that Curcumin potently
inhibits proliferation of GBM cells. Our data further
indicate that the efficacy of Curcumin can be explained
by interference with the JAK/STAT3-pathway. STAT3
inhibition represents a novel target in the treatment of
brain tumors. In its active form, STAT3 regulates a
number of pathways important in tumorigenesis includ-
ing cell cycle progression, migration, and invasion [30].
In gliomas, there are several reports on a constitutive
activation of STAT3 [31]. Normal cells, in contrast to
tumor cells are relatively tolerant to interruption of the
STAT3 signaling pathway, making STAT3 an excellent
target for molecular therapy of cancer [32,33]. Gliomas
seem to depend on activated STAT3: inhibition of
S T A T 3i sk n o w nt os u p p r e s sp r o l i f e r a t i o n[ 3 4 ] ,a n d
STAT3 knockdown reportedly induces apoptosis in
glioma cells [35]. Inhibition of STAT3 also leads to
reduced transcription of cell cycle regulating genes such
as c-Myc [30]. Here, we demonstrate that Curcumin
reduces intracellular levels of biologically active phos-
phorylated STAT3 in all GBM cell lines used contingent
on dose, which is paralleled by reduced transcription of
c-Myc and Ki-67. Thus, our data indicate that the effect
of Curcumin on GBM proliferation is mediated through
interference with the STAT3 signaling pathway. This
conclusion is in line with previous observations in other
cancers [36,37].
We did not observe significant induction of apoptosis
in our caspase assays. Therefore, the robust antiproli-
ferative effects of Curcumin as measured in the MTT
assays indeed reflect an inhibition of cell growth and
were not caused by an overall cell loss due to apoptosis
in the cultures. This finding is in line with previous
reports demonstrating cell cycle arrest caused by Curcu-
min [38].
In addition to cell growth, treatment with Curcumin
affected another hallmark of gliomas, i.e. migration and
invasion. We could recently demonstrate that interfer-
ence with the JAK/STAT3 pathway inhibits genomic
transcription of MMPs and results in decreased proteo-
lytic activity of MMPs 2 and 9 affecting GBM migration
and invasion [18]. Yet, in another report Curcumin
inhibited MMP gene expression through interference
with the MAP kinase pathway [39]. It is therefore possi-
ble, that the effects of Curcumin could partially be
exerted through several different molecular targets. Due
to the variety of potential interactions, it cannot be
ruled out that the observed anti-proliferative effect of
Curcumin might be exerted by interference with another
pathway in addition to JAK/STAT3. However, our study
strongly supports the hypothesis that STAT3 is one of
the key targets of Curcumin [36,40]. Likewise, several
other groups have reported STAT3 to be associated
with migration and invasion in glial as well as non-glial
tumors [41,42]. Finally, STAT3 was most recently con-
sidered to be a master regulator of human gliomas and
essential for maintaining tumor initiating capacity and
ability to invade the normal brain [43].
We have shown here that Curcumin potently hampers
GBM cell proliferation, migration, and invasion, and our
data suggest that this effect is mediated through inter-
ference with the JAK/STAT3 pathway. Given the fact
that STAT3 plays a key role in the mesenchymal trans-
formation of gliomas, which accompanies aggressive
behavior [43], STAT3 may also be a prime target to pre-
vent malignant transformation of low-grade gliomas.
Our data, along with existing reports in the literature,
indicate that Curcumin could become part of the thera-
peutic armamentarium in the multimodal treatment of
glioma patients. So far, Curcumin represents a safe and
low-cost drug, whose application in clinical practice,
even in high doses, in addition to conventional che-
motherapeutics is under investigation in early phase
clinical cancer trials [27]. In the future, experimental as
well as clinical studies e.g. regarding the combination of
Curcumin and temozolomide or Curcumin and radia-
tion therapy will further elucidate its therapeutic value
in malignant gliomas.
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Our data suggest that Curcumin is an effective agent to
target GBM cell proliferation as well as migration and
invasion. Its effects are at least partially mediated by
interference with the STAT3 signaling pathway. Exerting
anti-tumor properties without inducing toxicity, Curcu-
min represents a promising agent against GBM and
other cancers. Further analyses are warranted and neces-
sary to substantiate our findings.
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